GENE ONLINE|News &
Opinion
Blog

2021-03-23| In-DepthM&A

Overview of the Gene Therapy Revolution: Hopeful Beginnings, Tribulations, and Resurgence

by Rajaneesh K. Gopinath
Share To
Gene therapy is a hot commodity in the biopharma business, attracting profitable investments and expensive M&A transactions in recent years.

Moreover, the frequent reports of research breakthroughs and clinical trial gains are an indication of the steady progress of the field. In 2019, the gene therapy market was valued at $3.61 billion. It is predicted to grow further at a CAGR of 33.6% and reach $35.67 billion by 2027, according to a forecast released by Fortune Business Insights™.

GO Prime with only $1.49 now

LATEST
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14
Health Secretary Kennedy Retracts Parts of Agency Reorganization Plan During Combative Congressional Hearing
2025-05-14
SURMOUNT-5 Trial: Zepbound Shows Greater Weight Loss Than Wegovy
2025-05-14
ASCGT Meeting Navigates Biotech Downturn After Multi-Year Slump
2025-05-14
EVENT
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top